CHOP                                                 lymphoma(86)
 _________________________________________________________________
  cytoxan......... 750 mg/sqm IV day 1.
  adriamycin...... 50 mg/sqm IV day 1.
  vincristine..... 1.4 mg/sqm IV day 1.
  prednisone...... 100 mg/sqm/day orally from day 1 to day 5.
  FREQUENCY....... Repeat cycle every 3 weeks.

  reference...
    McKelvey EM.  Gottlieb JA.  Wilson HE.  Haut A.  Talley RW.  
    Stephens R. Lane M.  Gamble JF.  Jones SE.  Grozea PN.  
    Gutterman J.  Coltman C.  Moon TE. Hydroxyldaunomycin 
    (Adriamycin) combination chemotherapy in malignant lymphoma. 
    Cancer.  38(4):1484-93, 1976 Oct. 
  abstract...
    Combination chemotherapy with CHOP (cyclophosphamide, 
    Adriamycin, vincristine, and prednisone) and HOP (Adrimycin, 
    vincristine, and prednisone, was used as treatment for 
    patients with pathologically staged, advanced non-Hodgkin's 
    lymphoma. Among 204 evaluable patients treated on CHOP there 
    were 71% complete remissions with 92% overall responses. Among 
    the 216 evaluable patients on HOP there were 61% complete 
    remissions and 88% responses. Complete remission rates among 
    patients with histiocytic lymphoma were comparable to those of 
    patients with lymphocytic disease. Patients with nodular 
    lymphoma had higher rates of complete remission than their 
    counterparts with diffuse lymphoma. This was noted with both 
    CHOP (78% vs. 67%) and HOP (67% vs. 60%) induction therapy. 
    Rapid responses were common, as more than 14% of complete 
    remissions and 66% of overall responses were achieved with the 
    first course of treatment. Patients in complete remission have 
    been maintained with either cyclophosphamide, vincristine, and 
    prednisone (COP) or arabinosyl cytosine, vincristine, and 
    prednisone (OAP). After 1 year, 86% of patients on COP and 80% 
    on OAP are projected to be free of disease.